Myeloid neoplasm

There are 94 papers on myeloid neoplasm in aging research: 6 trials and 31 observational studies in people, 9 in animals, 2 in cells, 41 reviews. The newest story, Nov 13, 2026: “Blood DNA screen false positives rose with age”.

Disease

94 papers study it44 more mention it29 findings

17 new papers in 30 daysSee all 138 papers on myeloid neoplasm

At a glance

Human studies associate JAK2 in solid-tumor sequencing and clonal cytopenia with monocytosis of undetermined significance with myeloid neoplasms. Tet2 knockout induces myeloid neoplasms in mice. A review describes a plasma proteomic risk score predicting human myeloid neoplasms more than a decade before diagnosis.

29 findings in 27 papers from 2016 to 2026, 7 of them since August 2026

“CHIP was associated with higher risks of myeloid malignancies (HR 9.56, 95%CI 8.28-11.03)”
The joint association of clonal hematopoiesis of indeterminate potential and biological aging with cancer risk among 332,911 individualsJournal of the National Cancer Institute2026doi:10.1093/jnci/djag268
  • Human trial6
  • Humans31
  • Animals9
  • Cells2
  • In silico2

Upstream

2

TET2

upin mice1

1 study
  1. TET2 induces myeloid neoplasm in mice (Tet2 knockout).

    “Tet2 deficiency induced myeloid neoplasms with distinct age-dependent progression.”

    AnimalsTet2 knockout

    Tet2 deficiency drives age-related heterogeneous progression of myeloid neoplasms through epigenetic-immune microenvironment imbalance

    Journal of translational medicine

More on TET2

Human aging

upin humans1

1 study
  1. human aging increases myeloid neoplasm in humans.

    “With human aging there is an impaired immune response, loss of hematopoietic stem cell (HSC) function, increase in clonal hematopoiesis, and higher frequency of myeloid malignancies.”

    Review

    Human hematopoiesis: aging and leukemogenic risk

    Current opinion in hematology

Associations

20

Clonal hematopoiesis of indeterminate potential

upin humans6HR 9.56

6 studies
  1. Clonal hematopoiesis of indeterminate potential is linked with a higher risk of myeloid neoplasm in humans (HR 9.56, 95% CI 8.28-11.03).

    “CHIP was associated with higher risks of myeloid malignancies (HR 9.56, 95%CI 8.28-11.03)”

    Humansn = 332,911

    The joint association of clonal hematopoiesis of indeterminate potential and biological aging with cancer risk among 332,911 individuals

    Journal of the National Cancer Institute

  2. Clonal hematopoiesis of indeterminate potential predicts myeloid neoplasm in humans.

    “Deciphering CH enables precise risk stratification and helps intercept myeloid malignancies before clinical onset.”

    Review

    Silent, but not innocent: the emerging role of clonal hematopoiesis in predicting therapy-related myeloid neoplasms

    Frontiers in oncology

  3. Clonal hematopoiesis of indeterminate potential is associated with myeloid neoplasm in humans.

    “CH is associated with an increased risk of hematologic malignancies particularly myeloid neoplasms (MN)”

    Review

    Clonal hematopoiesis and its progression to myeloid neoplasms: insights into risk, biology, and therapeutic strategies

    Haematologica

  4. Clonal hematopoiesis of indeterminate potential raises the risk of myeloid neoplasm in humans.

    “Besides an increased risk of developing myeloid neoplasms”

    Review

    Influence of clonal hematopoiesis on non-hematological diseases and aging processes

    Innere Medizin (Heidelberg, Germany)

  5. Clonal hematopoiesis of indeterminate potential raises the risk of myeloid neoplasm in telomere biology disorder patients.

    “clonal hematopoiesis; increasing predisposition to MN”

    Reviewin telomere biology disorder patients

    Clonal Hematopoiesis and Myeloid Neoplasms in the Context of Telomere Biology Disorders

    Current hematologic malignancy reports

  6. Clonal hematopoiesis of indeterminate potential raises the risk of myeloid neoplasm in humans.

    “it is an independent risk factor for myeloid malignancy, cardiovascular disease (CVD), and all-cause mortality”

    Review

    Clonal hematopoiesis and associated diseases: A review of recent findings

    Cancer science

More on Clonal hematopoiesis of indeterminate potential

DDX41

upin humans2

2 studies
  1. DDX41 is associated with myeloid neoplasm in humans (germline variants) (approximately 50% by age 90).

    “Penetrance is nearly 0% by age 40 and approximately 50% by age 90, with comparable estimates in Japanese, UK, and French population datasets.”

    Reviewgermline variants

    DDX41-mutated myeloid neoplasms

    [Rinsho ketsueki] The Japanese journal of clinical hematology

  2. DDX41 is associated with myeloid neoplasm in humans (myeloid neoplasms) (2-5%).

    “DDX41 mutation accounts for 2-5% of myeloid neoplasms”

    Reviewmyeloid neoplasms

    Myeloid neoplasms with germline predisposition

    [Rinsho ketsueki] The Japanese journal of clinical hematology

More on DDX41

Somatic mutations in myeloid-driver genes

upin humans1HR 13.9

1 study
  1. Somatic mutations in myeloid-driver genes are linked with a higher risk of myeloid neoplasm in humans (subjects with inconclusive diagnostic findings) (HR 13.9, P < .001).

    “carrying 1 or more somatic mutations was associated with a high probability of developing a myeloid neoplasm during follow-up (hazard ratio = 13.9, P < .001)”

    Humanssubjects with inconclusive diagnostic findings

    Clinical significance of somatic mutation in unexplained blood cytopenia

    Blood

  2. Somatic mutations in myeloid-driver genes predict myeloid neoplasm in humans (unexplained cytopenia; variant allele frequency ≥0.10 or 2 or more mutations) (PPV 0.86 and 0.88).

    “Carrying a somatic mutation with a variant allele frequency ≥0.10, or carrying 2 or more mutations, had a positive predictive value for diagnosis of myeloid neoplasm equal to 0.86 and 0.88, respectively”

    Humansunexplained cytopenia; variant allele frequency ≥0.10 or 2 or more mutationsn = 683

    Clinical significance of somatic mutation in unexplained blood cytopenia

    Blood

More on Somatic mutations in myeloid-driver genes

Ultra-processed foods

upin humans1HR 1.12

1 study
  1. Ultra-processed foods are associated with myeloid neoplasm in humans (Without prevalent hospital-recorded myeloid neoplasms) (HR 1.12, 95% CI 1.05–1.21 per 1-SD higher UPF energy percentage).

    “Each 1-SD higher UPF energy percentage was associated with a higher hazard of myeloid neoplasms (HR, 1.12; 95% CI (1.05, 1.21); P = 0.001).”

    HumansWithout prevalent hospital-recorded myeloid neoplasmsEach 1-SD higher UPF energy percentageMedian 10.5 years of follow-upn = 204,494

    Higher ultra-processed food intake linked to some blood cancers

    The American journal of clinical nutrition

More on Ultra-processed foods

JAK2

upin humans1

1 study
  1. JAK2 is associated with myeloid neoplasm in humans (solid tumour NGS) (6/12 patients).

    “6/12 patients had evidence of a JAK2 V617F positive myeloid neoplasm”

    Humanssolid tumour NGSn = 12

    Incidental detection of JAK2 V617F mutations in next-generation sequencing analysis of solid tumours: a guide to further workup

    Journal of clinical pathology

More on JAK2

Clonal cytopenia with monocytosis of undetermined significance

upin humans1

1 study
  1. Clonal cytopenia with monocytosis of undetermined significance is linked with a higher risk of myeloid neoplasm in humans (median follow-up of 31 months) (13% (7/8 CMML)).

    “there were no progression events in CMUS patients, while 13% of CCMUS patients progressed to MN, mainly CMML (7/8).”

    Humansmedian follow-up of 31 monthsn = 64

    Clinical and molecular characteristics of clonal monocytosis with and without cytopenia(s)

    Leukemia

More on Clonal cytopenia with monocytosis of undetermined significance

Proteomic risk score

upin humans1

1 study
  1. Proteomic risk score predicts myeloid neoplasm in humans (over a decade before clinical diagnosis).

    “proteomic risk scores utilizing markers such as F7, BIN2, and CXCL11 can predict incident myeloid neoplasms”

    Reviewover a decade before clinical diagnosisplasma

    The proteomic architecture of clonal hematopoiesis: a systematic review of niche remodeling and multi-compartment predictors of malignant transformation

    Frontiers in medicine

More on Proteomic risk score

TP53

upin humans1

1 study
  1. TP53 is associated with myeloid neoplasm in humans (post cytotoxic therapy).

    “particularly those with TP53 or PPM1D mutations, which are strongly associated with myeloid neoplasms post cytotoxic therapy (MN-pCT).”

    Reviewpost cytotoxic therapy

    The interplay of clonal hematopoiesis and cancer: Clinical implications in oncology

    Cancer treatment reviews

More on TP53

Clonal cytopenia of undetermined significance

upin humans1

1 study
  1. Clonal cytopenia of undetermined significance raises the risk of myeloid neoplasm in humans.

    “clonal cytopenia of undetermined significance (CCUS), a recognized pre-malignant condition with a high risk of progression to myeloid neoplasms.”

    Review

    Clonal hematopoiesis and myeloid neoplasms: from molecular basis to clinical implications

    [Rinsho ketsueki] The Japanese journal of clinical hematology

More on Clonal cytopenia of undetermined significance

Clonal cytopenias of undetermined significance

upin humans1

1 study
  1. Clonal cytopenias of undetermined significance predicts myeloid neoplasm in humans.

    “CCUS is a precursor to myeloid neoplasms, with variable progression rates.”

    Review

    Clonal haematopoiesis to clonal cytopenias: unravelling disease evolution over time

    The Lancet. Haematology

More on Clonal cytopenias of undetermined significance

All 20

Trial sponsors

Funding

17 grants since 2019

National Cancer Institute$12MVetenskapsrådetSEK 17.1MEuropean Research Council€3.9M

Contains public sector information licensed under the Open Government Licence v3.0.

How this record changed

  1. Summary written from the findings.

Latest

Dec 2025: 4Jan 2026: 8Feb 2026: 6Mar 2026: 4Apr 2026: 1May 2026: 2Jun 2026: 2Jul 2026: 6Aug 2026: 7Sep 2026: 10Oct 2026: 7Nov 2026: 764 papers in 12 months
Research Square

Blood DNA screen false positives rose with age

False-positive rates rose from 0.3% below age 60 to 7.5% at 80 or older in an analysis of whole-blood samples.False-positive rates rose from 0.3% below age 60 to 7.5% at 80 or older in an analysis of whole-blood samples.

Preprint: cross-sectional studyBiomarkers
The American Journal of Clinical Nutrition

Higher ultra-processed food intake linked to some blood cancers

Higher intake was associated with more new blood cancer diagnoses among 204,494 UK Biobank participants followed for a median 10.5 years.Higher intake was associated with more new blood cancer diagnoses among 204,494 UK Biobank participants followed for a median 10.5 years.

Cohort · 204,494 peoplePopulations

See all 138 papers on myeloid neoplasm